Basel Medical Group LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Basel Medical Group Ltd. filed an amended annual report for fiscal year 2025, revealing a significant net loss primarily due to goodwill impairment from a recent acquisition, despite revenue growth.
NASDAQ
20-F: Basel Medical Group Reports Significant FY2025 Loss Amidst Goodwill Impairment and Auditor Concerns
Basel Medical Group Ltd. reported a substantial net loss for the fiscal year ended June 30, 2025, primarily driven by a significant goodwill impairment, alongside an auditor's disclaimer of opinion and identified material weaknesses in internal controls.